TY - JOUR AU - Burstein, H. J. AU - Mangu, P. B. AU - Somerfield, M. R. AU - Schrag, D. AU - Samson, D. AU - Holt, L. AU - Zelman, D. AU - Ajani, J. A. PY - 2011 DA - 2011// TI - American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.36.0354 DO - 10.1200/JCO.2011.36.0354 ID - Burstein2011 ER - TY - STD TI - NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer, version 1.2011j. [http://www.NCCN.org] UR - http://www.NCCN.org ID - ref2 ER - TY - JOUR AU - Kravtsov, V. AU - Fabian, I. PY - 1996 DA - 1996// TI - Automated monitoring of apoptosis in suspension cell cultures JO - Lab Invest VL - 74 ID - Kravtsov1996 ER - TY - JOUR AU - Kravtsov, V. AU - Greer, J. AU - Whitlock, J. PY - 1998 DA - 1998// TI - Use of the Microculture Kinetic (MiCK) Assay of apoptosis to determine chemosensitivity of leukemia’s JO - Blood VL - 92 ID - Kravtsov1998 ER - TY - JOUR AU - Kravtsov, V. AU - Greer, J. AU - Shyr, Y. PY - 2001 DA - 2001// TI - Prediction of survival in acute non-lymphocytic leukemia JO - Blood VL - 98 ID - Kravtsov2001 ER - TY - STD TI - Whitworth PW, Presant CA, Rutledge J: Chemosensitivity of patient breast cancer cells in vitro: Correlation with Prior Chemotherapy and Implications for Personalized Treatment Planning. J Clin Oncol. 2009, 27 (suppl; abstr e11563A): ID - ref6 ER - TY - JOUR AU - Ballard, K. S. AU - Homesley, H. D. AU - Hodson, C. PY - 2010 DA - 2010// TI - Endometrial carcinoma in-vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic (MiCK) apoptosis assay: implications for endometrial cancer treatment JO - J Gynecol Oncol VL - 21 UR - https://doi.org/10.3802/jgo.2010.21.1.45 DO - 10.3802/jgo.2010.21.1.45 ID - Ballard2010 ER - TY - BOOK PY - 2009 DA - 2009// TI - JMP version 8 ID - ref8 ER - TY - BOOK AU - Devore, J. L. PY - 1995 DA - 1995// TI - Probability and statistics for engineering and the sciences PB - Duxbury Press CY - CA ID - Devore1995 ER - TY - JOUR AU - Cox, D. R. PY - 1972 DA - 1972// TI - Regression models and life-tables. J Royal Statistical Society Series B – JO - Statistical Methodology VL - 34 ID - Cox1972 ER - TY - BOOK AU - Westfall, P. H. AU - Young, S. S. PY - 1993 DA - 1993// TI - Resampling based multiple testing: examples and methods for p-value adjustment PB - John Wiley and Sons CY - New York ID - Westfall1993 ER - TY - BOOK AU - Hsu, J. C. PY - 1996 DA - 1996// TI - Multiple comparisons: theory and methods PB - Chapman and Hall CY - New York UR - https://doi.org/10.1007/978-1-4899-7180-7 DO - 10.1007/978-1-4899-7180-7 ID - Hsu1996 ER - TY - STD TI - SAS/STAT 9.2 User’s Gide 2nd Edition. 2009, Cary: SAS Institute ID - ref13 ER - TY - JOUR AU - Bookman, M. A. AU - Brady, M. F. AU - McGuire, W. P. PY - 2009 DA - 2009// TI - Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer InterGroup JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.1684 DO - 10.1200/JCO.2008.19.1684 ID - Bookman2009 ER - TY - JOUR AU - Burger, R. A. PY - 2010 DA - 2010// TI - A phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer or fallopian tube cancer: a Gynecological Oncology Group study JO - J Clin Oncol VL - 28 ID - Burger2010 ER - TY - JOUR AU - DuBois, A. AU - Herrstedt, J. AU - Hardy-Bessard, A. PY - 2010 DA - 2010// TI - A Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.4696 DO - 10.1200/JCO.2009.27.4696 ID - DuBois2010 ER - TY - JOUR AU - Gallion, H. AU - Christopherson, W. A. AU - Coleman, R. L. PY - 2006 DA - 2006// TI - Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay JO - Int J Gynecol Cancer VL - 16 UR - https://doi.org/10.1111/j.1525-1438.2006.00301.x DO - 10.1111/j.1525-1438.2006.00301.x ID - Gallion2006 ER - TY - STD TI - ICON 2: randomized trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Cancer Neoplasm Study. Lancet. 1998, 352: 1571-1576. ID - ref18 ER - TY - JOUR PY - 2002 DA - 2002// TI - Paclitaxel plus carboplatin versus standard chemotherapy with single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON 3 randomized trial JO - Lancet VL - 360 UR - https://doi.org/10.1016/S0140-6736(02)09738-6 DO - 10.1016/S0140-6736(02)09738-6 ID - ref19 ER - TY - JOUR AU - Pfister, J. AU - Vergote, I. AU - DuBois, A. PY - 2005 DA - 2005// TI - Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer JO - Int J Gyneocol Cancer VL - 15 UR - https://doi.org/10.1111/j.1525-1438.2005.15355.x DO - 10.1111/j.1525-1438.2005.15355.x ID - Pfister2005 ER - TY - JOUR AU - Parmar, M. K. AU - Lederman, J. A. AU - Columbo, N. PY - 2003 DA - 2003// TI - ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON 4/AGO-OVAR-2.2 trial JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)13718-X DO - 10.1016/S0140-6736(03)13718-X ID - Parmar2003 ER - TY - STD TI - Latimer G, Presant CA, Hallquist A: The value of personalized treatment planning: cost savings by the microculture kinetic chemosensitivity assay, evidence from a large American self-insured company. J Clin Oncol. 2009, 27 (suppl; abstr e17541): ID - ref22 ER -